Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its drug CAMZYOS (mavacamten). The approval allows the drug to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients weighing at least 30 kg.
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval covers both adult and pediatric patients weighing 30 kg and above, aiming to improve functional c